StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Fri, 16 Oct 2026 08:13:01 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $4.00 price target on Engene Holdings Inc. (NASDAQ: ENGN).

The analyst commented: "Yesterday, EnGene hosted a KOL webinar to highlight how detalimogene aligns with real-world clinical decision making in NMIBC, and provide preclinical evidence supporting the newly added surfactant pre-rinse cohort in LEGEND. KOLs reiterated the multi-product nature of the NMIBC market, highlighting how bladder symptoms, comorbidities, travel burden, dosing frequency, and family-life logistics weigh as heavily as CR rates when choosing treatment options. The practical implication is that non-viral agents like detalimogene with lower bladder irritation and shorter dwell times

enGene to Host KOL Webinar on October 15, 2026

Tue, 13 Oct 2026 08:00:00 -0400

Community Key Opinion Leaders (KOLs) to present on real-world clinical decision making in high-risk non-muscle invasive bladder cancer (NMIBC)

Additional discussion to focus on preclinical data supporting incorporation of a surfactant bladder rinse plus detalimogene voraplasmid into clinical development

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into

enGene to Host KOL Webinar on October 15, 2026

Tue, 13 Oct 2026 08:00:00 -0400

Community Key Opinion Leaders (KOLs) to present on real-world clinical decision making in high-risk non-muscle invasive bladder cancer (NMIBC)

Additional discussion to focus on preclinical data supporting incorporation of a surfactant bladder rinse plus detalimogene voraplasmid into clinical development

Form 4 enGene Therapeutics Inc. For: Sep 22 Filed by: Grossman William

Thu, 24 Sep 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260924/27102676.html

Engene Holdings (ENGN) Reiterated at Market Perform by Citizens

Wed, 09 Sep 2026 04:17:16 -0400

Citizens analyst Silvan Turkcan reiterated a Market Perform rating on Engene Holdings Inc. (NASDAQ: ENGN).

The analyst commented, "enGene Holdings reported a 3Q26 update ahead of a key regulatory update and landmark CR rates from LEGEND in 4Q26, after which the company plans to file an IND. We met with ENGN management last week to discuss its view on the non-muscle invasive bladder cancer (NMIBC) market. We maintain our Market Perform rating with shares currently trading (~$122M market cap) at a 54% discount to cash reserves of $266M; therefore, we view shares as fairly valued, consistent with biotech peers facing similar

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932832.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26932832.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932220.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932220.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925050.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26925050.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26918741.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Invus Global Management, LLC

Thu, 13 Aug 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26918741.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26913527.html

Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260812/26913527.html

Form 8-K enGene Therapeutics Inc. For: Aug 11

Tue, 11 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26905492.html

Form 8-K enGene Therapeutics Inc. For: Aug 11

Tue, 11 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26905492.html

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

Tue, 04 Aug 2026 08:00:00 -0400

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations driving treatment selection.